Used in targeted cancer therapy, particularly for tumors driven by FGF19 signaling, such as hepatocellular carcinoma. Acts as a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), blocking downstream pathways involved in cell proliferation and survival. Currently under investigation in clinical trials to evaluate efficacy and safety in advanced solid tumors. Shows potential for treating patients with FGF19-positive cancers who have limited response to conventional therapies.